Ramana Kota V, Friedrich Brian, Tammali Ravinder, West Matthew B, Bhatnagar Aruni, Srivastava Satish K
Department of Human Biological Chemistry and Genetics, 6.644 Basic Science Building, University of Texas Medical Branch, Galveston, Texas 77555-0647, USA.
Diabetes. 2005 Mar;54(3):818-29. doi: 10.2337/diabetes.54.3.818.
Activation of protein kinase C (PKC) has been linked to the development of secondary diabetes complications. However, the underlying molecular mechanisms remain unclear. We examined the contribution of aldose reductase, which catalyzes the first, and the rate-limiting, step of the polyol pathway of glucose metabolism, to PKC activation in vascular smooth muscle cells (VSMCs) isolated from rat aorta and exposed to high glucose in culture. Exposure of VSMCs to high glucose (25 mmol/l), but not iso-osmotic mannitol, led to an increase in total membrane-associated PKC activity, which was prevented by the aldose reductase inhibitors tolrestat or sorbinil or by the ablation of aldose reductase by small interfering RNA (siRNA). The VSMCs were found to express low levels of sorbitol dehydrogenase, and treatment with the sorbitol dehydrogenase inhibitor CP-166572 did not prevent high-glucose-induced PKC activation. Stimulation with high glucose caused membrane translocation of conventional (alpha, beta1, beta2, and gamma) and novel (delta and epsilon) isoforms of PKC. Inhibition of aldose reductase prevented membrane translocation of PKC-beta2 and -delta and delayed the activation of PKC-beta1 and -epsilon, whereas membrane translocation of PKC-alpha and -gamma was not affected. Treatment with tolrestat prevented phosphorylation of PKC-beta2 and -delta. High glucose increased the formation of diacylglycerol (DAG) and enhanced phosphorylation of phospholipase C-gamma1 (PLC-gamma1). Inhibition of aldose reductase prevented high glucose-induced DAG formation and phosphorylation of PLC-gamma1 and PLC-beta2 and -delta. Inhibition of phospholipid hydrolysis by D609, but not by the synthetic alkyl-1-lysophospholipid 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine, or edelfosine, prevented DAG formation. Treatment with sorbinil decreased the levels of reactive oxygen species in high-glucose-stimulated VSMCs. Hence, inhibition of aldose reductase, independent of sorbitol dehydrogenase, appears to be effective in diminishing oxidative stress and hyperglycemic changes in signaling events upstream to the activation of multiple PKC isoforms and PLC-gamma1 and may represent a useful approach for preventing the development of secondary vascular complications of diabetes.
蛋白激酶C(PKC)的激活与继发性糖尿病并发症的发生有关。然而,其潜在的分子机制仍不清楚。我们研究了醛糖还原酶(催化葡萄糖代谢多元醇途径的第一步且为限速步骤)对从大鼠主动脉分离并在培养中暴露于高糖环境的血管平滑肌细胞(VSMC)中PKC激活的作用。将VSMC暴露于高糖(25 mmol/l)而非等渗甘露醇中,会导致总膜相关PKC活性增加,而醛糖还原酶抑制剂托瑞司他或索比尼尔,或通过小干扰RNA(siRNA)消除醛糖还原酶可阻止这种增加。发现VSMC表达低水平的山梨醇脱氢酶,用山梨醇脱氢酶抑制剂CP - 166572处理并不能阻止高糖诱导的PKC激活。高糖刺激导致传统型(α、β1、β2和γ)和新型(δ和ε)PKC同工型的膜转位。抑制醛糖还原酶可阻止PKC - β2和 - δ的膜转位,并延迟PKC - β1和 - ε的激活,而PKC - α和 - γ的膜转位不受影响。用托瑞司他处理可阻止PKC - β2和 - δ的磷酸化。高糖增加了二酰基甘油(DAG)的形成并增强了磷脂酶C - γ1(PLC - γ1)的磷酸化。抑制醛糖还原酶可阻止高糖诱导的DAG形成以及PLC - γ1、PLC - β2和 - δ的磷酸化。D609抑制磷脂水解可阻止DAG形成,而合成烷基 - 1 - 溶血磷脂1 - O - 十八烷基 - 2 - O - 甲基 - 外消旋甘油磷酸胆碱或依地福新则不能。用索比尼尔处理可降低高糖刺激的VSMC中的活性氧水平。因此,独立于山梨醇脱氢酶抑制醛糖还原酶似乎可有效减轻氧化应激以及多种PKC同工型和PLC - γ1激活上游信号事件中的高血糖变化,可能是预防糖尿病继发性血管并发症发生的一种有用方法。